Top

Cancer Chemotherapy and Pharmacology

Published in:

01-02-2018 | Original Article

Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic

Authors: Motoaki Ishikawa, Michiyasu Kawai, Toshio Maeda, Yoshiyuki Kagawa

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2018

Abstract

Purpose

Plasma paclitaxel (PTX) concentration 24 h or later after PTX administration may predict myelosuppression. Here, we explored predictive markers for neutropenia induced by intravenous administration of PTX in an outpatient clinic.

Methods

Thirty women suffering from uterine, ovarian or cervical cancer were enrolled in this study. PTX (mean dose: 167 mg/m²) was intravenously infused and followed by carboplatin. Plasma samples were obtained 4 h after PTX administration. Genotyping was carried out for CYP3A5*3, ABCB1 1236 C>T, 2677 G>T/A, and 3435 C>T.

Results

There was no significant relationship between genotype and reduced neutrophil count. Neutrophil reduction rate correlated with the patient’s height, neutrophil count on the day of administration, and plasma PTX concentration. Multiple regression analysis with those three indices explained 47.7% of the interindividual variability of the neutrophil reduction rate. The model with plasma PTX concentration, patient’s height, and plasma 6-α-hydroxy-paclitaxel /PTX concentration ratio also explained 30.0% of the interindividual variability for the neutrophil nadir count after PTX administration.

Conclusions

These results indicate that neutrophil reduction after PTX administration can be partially predicted by multiple regression analysis involving plasma concentration data collected at outpatient clinics.

Spratlin J, Sawyer MB (2007) Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 61(3):222–229. https://doi.org/10.1016/j.critrevonc.2006.09.006CrossRefPubMed

Rodríguez-Antona C (2010) Pharmacogenomics of paclitaxel. Pharmacogenomics 11(5):621–623. https://doi.org/10.2217/pgs.10.32CrossRefPubMed

Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47(9):2486–2493PubMed

Soyama A, Saito Y, Hanioka N et al (2001) Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 24(12):1427–1430. https://doi.org/10.1248/bpb.24.1427CrossRefPubMed

Nakajima M, Fujiki Y, Noda K et al (2003) Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 31(6):687–690. https://doi.org/10.1124/dmd.31.6.687CrossRefPubMed

Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT (2015) Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: Update of the literature. Clin Pharmacokinet 54:709–735. https://doi.org/10.1007/s40262-015-0267-1CrossRefPubMed

Iihara H, Fujii H, Yoshimi C, Yamada M, Suzuki A, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y (2016) Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. 21(2), 409–418. https://doi.org/10.1007/s10147-015-0908-2

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200CrossRefPubMed

Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E,et al (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14(10):1020–1026CrossRefPubMed

10.

Gianni L, Kearns CM, Giani A et al (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13(1):180–190. https://doi.org/10.1200/JCO.1995.13.1.180CrossRefPubMed

11.

Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1(6):599–606PubMed

12.

Joerger M, Huitema AD, Richel DJ et al (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13(21):6410–6418. https://doi.org/10.1158/1078-0432.CCR-07-0064CrossRefPubMed

13.

Basileo G, Breda M, Fonte G, Pisano R, James CA (2003) Quantitative determination of paclitaxel in human plasma using semi-automated liquid-liquid extraction in conjunction with liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 32(4–5):591–600. https://doi.org/10.1016/S0731-7085(03)00166-3CrossRefPubMed

14.

Balram C, Zhou Q, Cheung YB, Lee EJ (2003) CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 59(2):123–126. https://doi.org/10.1007/s00228-003-0594-2CrossRefPubMed

15.

Jelliffe RW, Jelliffe SM (1971) Estimation of creatinine clearance from changing serum-creatinine levels. Lancet 7726(2):710CrossRef

16.

Panday VR, Huizing MT, van Warmerdam LJ et al (1998) Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer. 3(38), 231–236. https://doi.org/10.1006/phrs.1998.0360

17.

Tanabe M, Ieiri I, Nagata N et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297(3):1137–1143PubMed

18.

Jiko M, Yano I, Sato E et al (2007) Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol 12(4):284–290. https://doi.org/10.1007/s10147-007-0681-yCrossRefPubMed

19.

Pfeil AM, Vulsteke C, Paridaens R et al (2014) Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. BMC Cancer, 201(14). https://doi.org/10.1186/1471-2407-14-201

20.

Henningsson A, Marsh S, Loos WJ et al (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11(22):8097–8104. https://doi.org/10.1158/1078-0432.CCR-05-1152CrossRefPubMed

21.

Rodriguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, Ingelman-Sundberg M (2008) Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 8(4):268–277. https://doi.org/10.1038/sj.tpj.6500482CrossRefPubMed

22.

Nakajima M, Fujiki Y, Kyo S et al (2005) Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 45(6):674–682. https://doi.org/10.1177/0091270005276204CrossRefPubMed

23.

Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C (2008) Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol 104:130–137. https://doi.org/10.1111/j.1742-7843.2008.00351.xCrossRef

24.

Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. 25(29), 4528–4535. https://doi.org/10.1200/JCO.2006.10.4752

Title: Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic
Authors: Motoaki Ishikawa
Michiyasu Kawai
Toshio Maeda
Yoshiyuki Kagawa
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3506-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells

A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II data and model application for drug–drug interaction potential analysis

Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study

Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men

Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer